[ad_1]
US authorities have approved the drug donanemab for the treatment of Alzheimer’s disease. The drug can slow the early stages of the disease.
Short version
- US authorities have approved a new drug to treat Alzheimer’s disease.
- The drug slows down the early progression of the disease and is sold under the name Kisunla.
- Test results showed it could slow memory loss and thinking impairment for up to seven months.
The drug is manufactured by Eli Lilly and sold under the brand name Kisunla. It is indicated for patients with mild or early dementia caused by Alzheimer’s disease.
This is the second anti-Alzheimer’s drug approved by the US FDA. Lecanemab, marketed as Leqembi, was approved last year. It is sold by Eisai in Japan.
They are both antibodies created in the lab. They work by attacking the buildup of so-called sticky amyloid plaques in the brain.
Tests showed that both drugs, which have possible side effects, slowed the rate at which memory and thinking deteriorated by up to seven months.
Doctors who treat Alzheimer’s disease said the approval was an important step after decades of experimental treatments failing.
– I’m excited about the different opportunities to help my patients. I diagnose patients with Alzheimer’s, and then I see their disease getting worse every year until they die, Suzanne Schindler, a neurologist at Washington University in St. Louis, told the Associated Press.
[ad_2]
Source link
